# 68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer

> **NCT02282137** · PHASE2 · UNKNOWN · sponsor: **Ebrahim Delpassand** · enrollment: 208 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 68Ga-PSMA

## Key facts

- **NCT ID:** NCT02282137
- **Lead sponsor:** Ebrahim Delpassand
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-05
- **Primary completion:** 2022-12
- **Final completion:** 2023-12
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2020-08-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02282137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02282137, "68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02282137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*